Daria Lucia Trabattoni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2172095/publications.pdf

Version: 2024-02-01

176 papers 8,506 citations

52 h-index 54882 84 g-index

181 all docs

181 docs citations

times ranked

181

10859 citing authors

#	Article	IF	CITATIONS
1	Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clinical and Experimental Immunology, 1996, 106, 127-133.	1.1	557
2	HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nature Medicine, 1997, 3, 1250-1257.	15.2	399
3	Analysis of SARS-CoV-2 vertical transmission during pregnancy. Nature Communications, 2020, 11, 5128.	5 . 8	284
4	HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. Aids, 1999, 13, 23-29.	1.0	235
5	Cytokine Production Patterns in Cervical Intraepithelial Neoplasia: Association With Human Papillomavirus Infection. Journal of the National Cancer Institute, 1997, 89, 245-250.	3.0	232
6	UV-C irradiation is highly effective in inactivating SARS-CoV-2 replication. Scientific Reports, 2021, 11, 6260.	1.6	207
7	Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA―pilot randomized trial. Mucosal Immunology, 2011, 4, 554-563.	2.7	177
8	Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy–treated immunologic nonresponders. Blood, 2011, 118, 3263-3272.	0.6	158
9	B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood, 2003, 101, 2514-2520.	0.6	157
10	Productive Infection Maintains a Dynamic Steady State of Residual Viremia in Human Immunodeficiency Virus Type 1-Infected Persons Treated with Suppressive Antiretroviral Therapy for Five Years. Journal of Virology, 2003, 77, 11212-11219.	1.5	136
11	Human Immunodeficiency Virus (HIV)–Specific IgA and HIV Neutralizing Activity in the Serum of Exposed Seronegative Partners of HIVâ€Seropositive Persons. Journal of Infectious Diseases, 1999, 180, 871-875.	1.9	135
12	Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. Neurobiology of Aging, 2004, 25, 1009-1015.	1.5	131
13	Treatment of periodontal disease results in improvements in endothelial dysfunction and reduction of the carotid intimaâ€media thickness. FASEB Journal, 2009, 23, 1196-1204.	0.2	127
14	Cross-Clade HIV-1â€"Specific Neutralizing IgA in Mucosal and Systemic Compartments of HIV-1â€"Exposed, Persistently Seronegative Subjects. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 30, 413-420.	0.9	118
15	Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy. Aids, 2010, 24, 1991-2000.	1.0	116
16	Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. Aids, 2000, 14, 2083-2092.	1.0	112
17	The â€~immunologic advantage' of HIV-exposed seronegative individuals. Aids, 2009, 23, 161-175.	1.0	106
18	Probiotics Reduce Gut Microbial Translocation and Improve Adult Atopic Dermatitis. Journal of Clinical Gastroenterology, 2012, 46, S33-S40.	1.1	104

#	Article	IF	Citations
19	Cytokines production in chronic schizophrenia patients with or without paranoid behaviour. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1998, 22, 947-957.	2.5	99
20	Type 1 Cytokine Production and Low Prevalence of Viral Isolation Correlate with Long-Term Nonprogression in HIV Infection. AIDS Research and Human Retroviruses, 1996, 12, 1053-1061.	0.5	94
21	One night on-call: Sleep deprivation affects cardiac autonomic control and inflammation in physicians. European Journal of Internal Medicine, 2013, 24, 664-670.	1.0	94
22	T-helper cell responses to HIV envelope peptides in cord blood: protection against intrapartum and breast-feeding transmission. Aids, 2001, 15, 1-9.	1.0	93
23	Apolipoprotein B mRNA–Editing Enzyme, Catalytic Polypeptide–Like 3G: A Possible Role in the Resistance to HIV of HIVâ€Exposed Seronegative Individuals. Journal of Infectious Diseases, 2007, 195, 960-964.	1.9	87
24	Immune Profiles of Patients with Chronic Idiopathic Urticaria. International Archives of Allergy and Immunology, 2002, 128, 59-66.	0.9	86
25	Cytokine profiles in schizophrenic patients treated with risperidone. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 33-39.	2.5	86
26	PIN1 promoter polymorphisms are associated with Alzheimer's disease. Neurobiology of Aging, 2007, 28, 69-74.	1.5	86
27	Antiretroviral therapy-associated modulation of Th1 and Th2 immune responses in HIV-infected pregnant women. Journal of Reproductive Immunology, 2006, 70, 143-150.	0.8	85
28	IL-22 Participates in an Innate Anti-HIV-1 Host-Resistance Network through Acute-Phase Protein Induction. Journal of Immunology, 2007, 178, 407-415.	0.4	83
29	Costimulatory Pathways in Multiple Sclerosis: Distinctive Expression of PD-1 and PD-L1 in Patients with Different Patterns of Disease. Journal of Immunology, 2009, 183, 4984-4993.	0.4	83
30	Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men. Aids, 2003, 17, 531-539.	1.0	80
31	Cytokine Polymorphisms in the Pathophysiology of Mood Disorders. CNS Spectrums, 2009, 14, 419-425.	0.7	80
32	Immune activation in HIV-infected African individuals. Aids, 1998, 12, 2387-2396.	1.0	77
33	TLR Activation Pathways in HIV-1–Exposed Seronegative Individuals. Journal of Immunology, 2010, 184, 2710-2717.	0.4	76
34	Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the \hat{l} ±-helix of gp41. Aids, 2002, 16, 1731-1741.	1.0	75
35	Immunomodulatory Effects of 1,25-Dihydroxyvitamin D3 on TH1/TH2 Cytokines in Inflammatory Bowel Disease: An <i>in Vitro</i> Study. International Journal of Immunopathology and Pharmacology, 2009, 22, 63-71.	1.0	74
36	Designing nanomolar antagonists of DC-SIGN-mediated HIV infection: ligand presentation using molecular rods. Chemical Communications, 2015, 51, 3816-3819.	2.2	74

#	Article	IF	Citations
37	Human α Defensin in HIV-Exposed But Uninfected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 455-463.	0.9	73
38	A possible role for the cortisol/anticortisols imbalance in the progression of human immunodeficiency virus. Psychoneuroendocrinology, 1997, 22, S27-S31.	1.3	72
39	Detection of Mucosal Antibodies in HIV Type 1-Infected Individuals. AIDS Research and Human Retroviruses, 2002, 18, 1291-1300.	0.5	72
40	Immunologic characterization of children vertically infected with human immunodeficiency virus, with slow or rapid disease progression. Journal of Pediatrics, 1995, 126, 368-374.	0.9	71
41	The NLRP3 Inflammasome Is Upregulated in HIV-Infected Antiretroviral Therapy-Treated Individuals with Defective Immune Recovery. Frontiers in Immunology, 2018, 9, 214.	2.2	71
42	Multiple inflammasome complexes are activated in autistic spectrum disorders. Brain, Behavior, and Immunity, 2016, 57, 125-133.	2.0	67
43	Post-kala-azar Dermal Leishmaniasis During Highly Active Antiretroviral Therapy in an AIDS Patient Infected withLeishmania infantum. Journal of Infection, 2000, 40, 199-202.	1.7	63
44	Lowâ€Dose Prolonged Intermittent Interleukinâ€2 Adjuvant Therapy: Results of a Randomized Trial among Human Immunodeficiency Virus–Positive Patients with Advanced Immune Impairment. Journal of Infectious Diseases, 2002, 186, 606-616.	1.9	63
45	In vivo imaging of immune cell trafficking in cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 949-968.	3.3	63
46	CD4+CD25+FoxP3+PD1— regulatory T cells in acute and stable relapsingâ€remitting multiple sclerosis and their modulation by therapy. FASEB Journal, 2008, 22, 3500-3508.	0.2	62
47	Upregulation of inflammasome activity and increased gut permeability are associated with obesity in children and adolescents. International Journal of Obesity, 2016, 40, 1026-1033.	1.6	60
48	The PD-1/PD-L1 Pathway in Human Pathology. Current Molecular Medicine, 2012, 12, 259-267.	0.6	58
49	A glycomimetic compound inhibits DC-SIGN-mediated HIV infection in cellular and cervical explant models. Aids, 2012, 26, 127-137.	1.0	58
50	Single-cell analysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent disease. Journal of Neuroimmunology, 2001, 121, 88-101.	1.1	54
51	Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. Vaccine, 2014, 32, 5657-5661.	1.7	54
52	Immunological Effects of Sublingual Immunotherapy: Clinical Efficacy Is Associated with Modulation of Programmed Cell Death Ligand 1, IL-10, and IgG4. Journal of Immunology, 2010, 185, 7723-7730.	0.4	53
53	Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn's disease. Digestive and Liver Disease, 2011, 43, 946-952.	0.4	53
54	Hiv-specific secretory IgA in breast milk of HIV-positive mothers is not associated with protection against HIV transmission among breast-fed infants. Journal of Pediatrics, 2006, 149, 611-616.	0.9	52

#	Article	IF	CITATIONS
55	No cure of HIV infection in a child despite early treatment and apparent viral clearance. Lancet, The, 2014, 384, 1320.	6.3	52
56	Chemokine production in HIV-seropositive long-term asymptomatic individuals. Aids, 1996, 10, 1432-1433.	1.0	51
57	CD4+ T Cell Depletion, Immune Activation and Increased Production of Regulatory T Cells in the Thymus of HIV-Infected Individuals. PLoS ONE, 2010, 5, e10788.	1.1	51
58	Thiazolides Elicit Anti-Viral Innate Immunity and Reduce HIV Replication. Scientific Reports, 2016, 6, 27148.	1.6	49
59	HLA and Autoimmune Digestive Disease: A Clinically Oriented Review for Gastroenterologists. American Journal of Gastroenterology, 2009, 104, 195-217.	0.2	48
60	Cholecalciferol Supplementation in HIV-Infected Youth with Vitamin D Insufficiency: Effects on Vitamin D Status and T-Cell Phenotype: A Randomized Controlled Trial. HIV Clinical Trials, 2013, 14, 51-60.	2.0	47
61	Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals. Aids, 2013, 27, 381-389.	1.0	46
62	Severity of COVID-19 Patients Predicted by Serum Sphingolipids Signature. International Journal of Molecular Sciences, 2021, 22, 10198.	1.8	45
63	Evidence for type 2 cytokine production and lymphocyte activation in the early phases of HIV-1 infection. Aids, 1996, 10, 23-30.	1.0	44
64	Type 1 and Type 2 Cytokines in HIV Infection $\hat{a}\in$ A Possible Role in Apoptosis and Disease Progression. Annals of Medicine, 1997, 29, 185-188.	1.5	44
65	Immunization with Both T Cell-Dependent and T Cell-Independent Vaccines Augments HIV Viral Load Secondarily to Stimulation of Tumor Necrosis Factor $\hat{I}\pm$. AlDS Research and Human Retroviruses, 1998, 14, 727-734.	0.5	43
66	Neurocognitive Impairment in HIV-Infected Na \tilde{A} -ve Patients with Advanced Disease: The Role of Virus and Intrathecal Immune Activation. Clinical and Developmental Immunology, 2012, 2012, 1-5.	3.3	43
67	Alpha-defensins in the prevention of HIV transmission among breastfed infants. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 39, 138-42.	0.9	43
68	Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response. Journal of Clinical Immunology, 2015, 35, 550-557.	2.0	42
69	Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. Journal of Medical Virology, 2006, 78, 440-445.	2.5	40
70	Interferon- \hat{I}^3 and Granulocyte-Macrophage Colony Stimulating Factor Therapy in Three Patients with Pulmonary Aspergillosis. Infection, 2008, 36, 368-373.	2.3	39
71	Short Communication: Immune Activation Is Present in HIV-1-Exposed Seronegative Individuals and Is Independent of Microbial Translocation. AIDS Research and Human Retroviruses, 2016, 32, 129-133.	0.5	39
72	Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naĀ-ve patients with undetectable viraemia. Aids, 2000, 14, 109-116.	1.0	38

#	Article	IF	Citations
7 3	Granule-dependent mechanisms of lysis are defective in CD8 T cells of HIV-infected, antiretroviral therapy-treated individuals. Aids, 2004, 18, 859-869.	1.0	36
74	T Lymphocyte Maturation Is Impaired in Healthy Young Individuals Carrying Trisomy 21 (Down) Tj ETQq0 0 0 rgBT	/8.verlock	10 Tf 50 70
7 5	Pseudo-Mannosylated DC-SIGN Ligands as Immunomodulants. Scientific Reports, 2016, 6, 35373.	1.6	36
76	The MCP-1 Gene (SCYA2) and Mood Disorders: Preliminary Results of a Case-Control Association Study. NeuroImmunoModulation, 2010, 17, 126-131.	0.9	35
77	Distinct patterns of HIV-specific memory T lymphocytes in HIV-exposed uninfected individuals and in HIV-infected patients. Aids, 2005, 19, 653-661.	1.0	34
78	Multiple defects of T helper cell function in newly diagnosed patients with Hodgkin's disease. European Journal of Cancer, 1994, 30, 1464-1470.	1.3	33
79	Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection. Journal of Pediatrics, 1999, 135, 675-682.	0.9	33
80	Skewed T-cell maturation and function in HIV-infected patients failing CD4+ recovery upon long-term virologically suppressive HAART. Aids, 2010, 24, 1455-1460.	1.0	33
81	Immune responses to antigens of human endogenous retroviruses in patients with acute or stable multiple sclerosis. Journal of Neuroimmunology, 1999, 99, 173-182.	1.1	32
82	Growth hormone in T-lymphocyte thymic and postthymic development: A study in HIV-infected children. Journal of Pediatrics, 2004, 145, 542-548.	0.9	32
83	Genotypes at chromosome 22q12-13 are associated with HIV-1-exposed but uninfected status in Italians. Aids, 2005, 19, 1015-1024.	1.0	32
84	Interferon-Gamma and Interleukin-10 Production Among HIV-1–Infected and Uninfected Infants of HIV-1–Infected Mothers. Pediatric Research, 2001, 50, 412-416.	1.1	31
85	Interleukin 21 (IL-21)/microRNA-29 (miR-29) axis is associated with natural resistance to HIV-1 infection. Aids, 2018, 32, 2453-2461.	1.0	31
86	Intractable pruritus in HIV infection: immunologic characterization. Allergy: European Journal of Allergy and Clinical Immunology, 1999, 54, 266-272.	2.7	30
87	Immunomodulatory activity of pidotimod administered with standard antibiotic therapy in children hospitalized for community-acquired pneumonia. Journal of Translational Medicine, 2015, 13, 288.	1.8	30
88	Protease Inhibitor–Associated Increased Risk of Preterm Delivery Is an Immunological Complication of Therapy. Journal of Infectious Diseases, 2007, 195, 914-916.	1.9	28
89	CCL28 Induces Mucosal Homing of HIV-1-Specific IgA-Secreting Plasma Cells in Mice Immunized with HIV-1 Virus-Like Particles. PLoS ONE, 2011, 6, e26979.	1.1	28
90	Endoplasmic reticulum aminopeptidase 2 haplotypes play a role in modulating susceptibility to HIV infection. Aids, 2013, 27, 1697-1706.	1.0	28

#	Article	IF	CITATIONS
91	Evolutionary Analysis Identifies an MX2 Haplotype Associated with Natural Resistance to HIV-1 Infection. Molecular Biology and Evolution, 2014, 31, 2402-2414.	3.5	28
92	Distinct immune profiles characterize patients with diffuse or limited systemic sclerosis. Clinical Immunology, 2003, 108, 21-28.	1.4	27
93	Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy. PLoS ONE, 2016, 11, e0146622.	1.1	27
94	Solar UV-B/A radiation is highly effective in inactivating SARS-CoV-2. Scientific Reports, 2021, 11, 14805.	1.6	27
95	Failure to eradicate HIV despite fully successful HAART initiated in the first days of life. Journal of Pediatrics, 2006, 148, 389-391.	0.9	26
96	A role for Waldeyer's ring in immunological response to allergens. Current Medical Research and Opinion, 2014, 30, 203-205.	0.9	26
97	The Mucosae-Associated Epithelial Chemokine (MEC/CCL28) Modulates Immunity in HIV Infection. PLoS ONE, 2007, 2, e969.	1.1	26
98	Pseudo-Mannosylated DC-SIGN Ligands as Potential Adjuvants for HIV Vaccines. Viruses, 2014, 6, 391-403.	1.5	25
99	Immunomodulatory effects of pidotimod in adults with community-acquired pneumonia undergoing standard antibiotic therapy. Pulmonary Pharmacology and Therapeutics, 2017, 44, 24-29.	1.1	25
100	Pentoxyfylline Improves Cell-Mediated Immunity and Reduces Human Immunodeficiency Virus (HIV) Plasma Viremia in Asymptomatic HIV-Seropositive Persons. Journal of Infectious Diseases, 1997, 175, 1210-1215.	1.9	24
101	Maraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected Patients. Scientific Reports, 2016, 6, 28853.	1.6	24
102	Endoplasmic Reticulum Associated Aminopeptidase 2 (ERAP2) Is Released in the Secretome of Activated MDMs and Reduces in vitro HIV-1 Infection. Frontiers in Immunology, 2019, 10, 1648.	2.2	24
103	Thymic volume predicts long-term immune reconstitution in HIV-infected children treated with highly active antiretroviral therapy. Aids, 2002, 16, 2219-2221.	1.0	22
104	Retinoids, breast cancer and NK cells. British Journal of Cancer, 1993, 68, 845-850.	2.9	21
105	Virologie and Immunologic Markers of Disease Progression in Pediatrie HIV Infection. AIDS Research and Human Retroviruses, 1996, 12, 1255-1262.	0.5	21
106	Programmed cell death of myelin basic protein-specific T lymphocytes is reduced in patients with acute multiple sclerosis. Journal of Neuroimmunology, 2005, 166, 173-179.	1.1	21
107	A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6–35 months. Vaccine, 2010, 28, 6137-6144.	1.7	21
108	Identification of a Specific miRNA Profile in HIV-Exposed Seronegative Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 11-19.	0.9	21

#	Article	IF	CITATIONS
109	Synergy between mannose-binding lectin gene polymorphisms and supplementation with vitamin A influences susceptibility to HIV infection in infants born to HIV-positive mothers. American Journal of Clinical Nutrition, 2006, 84, 610-615.	2.2	19
110	In Vivo Imaging of Lymph Node Migration of MNP- and 111In-Labeled Dendritic Cells in a Transgenic Mouse Model of Breast Cancer (MMTV-Ras). Molecular Imaging and Biology, 2012, 14, 183-196.	1.3	19
111	Selective granulocyte/monocyte apheresis in the treatment of HIV-infected patients: short-term and long-term effects on immunological and virological parameters. Perfusion (United Kingdom), 2002, 17, 47-51.	0.5	18
112	Reduced HIV-stimulated T-helper cell reactivity in cord blood with short-course antiretroviral treatment for prevention of maternal-infant transmission. Clinical and Experimental Immunology, 2001, 123, 443-450.	1.1	17
113	Assessment of immune reconstitution to Pneumocystis carinii in HIV-1 patients under different highly active antiretroviral therapy regimens. Journal of Antimicrobial Chemotherapy, 2003, 52, 276-281.	1.3	17
114	A role for mucosal immunity in resistance to HIV infection. Immunology Letters, 1999, 66, 21-25.	1.1	16
115	Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patients. Aids, 2002, 16, 1767-1773.	1.0	16
116	Immune activation and normal levels of endogenous antivirals are seen in healthy adolescents born of HIV-infected mothers. Aids, 2007, 21, 245-248.	1.0	16
117	Effects of Specific Immunotherapy on the B7 Family of Costimulatory Molecules in Allergic Inflammation. Journal of Immunology, 2007, 178, 1931-1937.	0.4	16
118	Qualitative Immune Modulation by Interleukin-2 (IL-2) Adjuvant Therapy in Immunological Non Responder HIV-Infected Patients. PLoS ONE, 2010, 5, e14119.	1.1	16
119	High Expression of Antiviral and Vitamin D Pathway Genes Are a Natural Characteristic of a Small Cohort of HIV-1-Exposed Seronegative Individuals. Frontiers in Immunology, 2017, 8, 136.	2.2	15
120	Unlikely SARS-CoV-2 Transmission During Vaginal Delivery. Reproductive Sciences, 2021, 28, 2939-2941.	1.1	15
121	Evaluation of Immune Activation in HIV-Infected and Uninfected African Individuals by Single-Cell Analysis of Cytokine Production. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 429-436.	0.9	14
122	Long-Term Resistance to HIV Infection in Vertical HIV Infection: Cytokine Production, HIV Isolation, and HIV Phenotype Define Long-Term Resistant Hosts. Pathobiology, 1997, 65, 169-176.	1.9	13
123	Tumor Necrosis Factor–α Increased Production during Thalidomide Treatment in Patients with Tuberculosis and Human Immunodeficiency Virus Coinfection. Journal of Infectious Diseases, 2000, 182, 639-639.	1.9	13
124	A Regulatory Polymorphism in HAVCR2 Modulates Susceptibility to HIV-1 Infection. PLoS ONE, 2014, 9, e106442.	1.1	13
125	Immunomodulating activity of Pidotimod in children with Down syndrome. Journal of Biological Regulators and Homeostatic Agents, 2013, 27, 253-8.	0.7	13
126	Immunomodulation Induced by Tucaresol in HIV Infection: Results of a 16 Week Pilot Phase I/II Trial. Antiviral Therapy, 2004, 9, 603-614.	0.6	13

#	Article	IF	CITATIONS
127	Sterol metabolism modulates susceptibility to HIV-1 Infection. Aids, 2020, 34, 1593-1602.	1.0	12
128	Restorative effect of total parenteral nutrition on natural killer cell activity in malnourished cancer patients. European Journal of Cancer, 1995, 31, 2023-2027.	1.3	11
129	Effect of two different combinations of antiretrovirals (AZT+ddl and AZT+3TC) on cytokine production and apoptosis in asymptomatic HIV infection. Antiviral Research, 2000, 46, 171-179.	1.9	11
130	Emergency Lung Transplantation after COVID-19: Immunopathological Insights on Two Affected Patients. Cells, 2021, 10, 611.	1.8	11
131	IL-4 and CXCR4 upregulation in HIV-infected and uninfected individuals from Maharashtra-Mumbai. Aids, 2003, 17, 1563-1565.	1.0	10
132	The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses. International Journal of Molecular Sciences, 2017, 18, 2127.	1.8	10
133	Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculosis disease. Aids, 2000, 14, 1859-1861.	1.0	10
134	Modulation of Human Immunodeficiency Virus (HIV)-Specific Immune Response by Using Efavirenz, Nelfinavir, and Stavudine in a Rescue Therapy Regimen for HIV-Infected, Drug-Experienced Patients. Vaccine Journal, 2002, 9, 1114-1118.	3.2	9
135	Research on Psychoimmunology. World Journal of Biological Psychiatry, 2003, 4, 119-123.	1.3	9
136	Human papilloma virus vaccination induces strong human papilloma virus specific cell-mediated immune responses in HIV-infected adolescents and young adults. Aids, 2015, 29, 739-743.	1.0	9
137	A 6-amino acid insertion/deletion polymorphism in the mucin domain of TIM-1 confers protections against HIV-1 infection. Microbes and Infection, 2017, 19, 69-74.	1.0	9
138	Forcing Seasonality of Influenza-like Epidemics with Daily Solar Resonance. IScience, 2020, 23, 101605.	1.9	9
139	Transient Detection of Plasma HIV-1 RNA During Postexposure Prophylaxis. Infection Control and Hospital Epidemiology, 2000, 21, 529-531.	1.0	8
140	Humoral and cell-mediated immune responses after a booster dose of HBV vaccine in HIV-infected children, adolescents and young adults. PLoS ONE, 2018, 13, e0192638.	1.1	8
141	Immunological Characterization of HIV and SARS-CoV-2 Coinfected Young Individuals. Cells, 2021, 10, 3187.	1.8	8
142	Aminooxypentane-RANTES, an Inhibitor of R5 Human Immunodeficiency Virus Type 1, Increases the Interferon gamma to Interleukin 10 Ratio without Impairing Cellular Proliferation. AIDS Research and Human Retroviruses, 1999, 15, 861-867.	0.5	7
143	Low interleukin-10 production is associated with diabetes in HIV-infected patients undergoing antiviral therapy. Medical Microbiology and Immunology, 2006, 195, 125-132.	2.6	7
144	The Effects of CD40 Ligation on Peripheral Blood Mononuclear Cell Interleukin-12 and Interleukin-15 Production and on Monocyte CD14 Surface Antigen Expression in Human Immunodeficiency Virus-Positive Patients. Scandinavian Journal of Immunology, 1999, 49, 286-292.	1.3	6

#	Article	lF	Citations
145	Vaccine strategies for infectious diseases. Expert Opinion on Investigational Drugs, 1999, 8, 95-106.	1.9	6
146	Cytokine production in women with antiretroviral treatment-associated breast fat accumulation and limb wasting. Aids, 2003, 17, S155-S161.	1.0	6
147	Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice. Vaccine, 2006, 24, 1470-1477.	1.7	6
148	Prospective Immune Dynamics during the First 24 Weeks of Efavirenz Based-Antiretroviral Therapy in HIV-1-Infected Subjects, According to CD4+ T-Cell Counts at Presentation: The IMMUNEF Clinical Trial. PLoS ONE, 2015, 10, e0117118.	1,1	6
149	Evaluation of Th9 lymphocytes in peripheral blood of rheumatoid arthritis patients and correlation with anti-tumor necrosis factor therapy: results from an in vitro pivotal study. Reumatismo, 2016, 68, 83-89.	0.4	6
150	Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen. Journal of Antimicrobial Chemotherapy, 2018, 73, 2162-2170.	1.3	6
151	IL-21 is associated with natural resistance to HIV-1 infection in a Colombian HIV exposed seronegative cohort. Microbes and Infection, 2020, 22, 371-374.	1.0	5
152	ERAPs Reduce In Vitro HIV Infection by Activating Innate Immune Response. Journal of Immunology, 2021, 206, 1609-1617.	0.4	5
153	Pregnant Women Develop a Specific Immunological Long-Lived Memory Against SARS-COV-2. Frontiers in Immunology, 2022, 13, 827889.	2.2	5
154	Study of immunological and virological parameters during thalidomide treatment of SIV-infected cynomolgus monkeys. Journal of Medical Primatology, 2000, 29, 1-10.	0.3	4
155	Unusual presentation of acute cytomegalovirus disease during primary HIV-1 infection: antigen-specific T-cell response analyses and clinical outcome. Aids, 2006, 20, 1566-1567.	1.0	4
156	An Immunological Comparison of Third Companion in Advanced Drug-Naive HIV-Infected Patients. HIV Clinical Trials, 2006, 7, 221-228.	2.0	4
157	Fully Immunocompetent CD8+ T Lymphocytes Are Present in Autologous Haematopoietic Stem Cell Transplantation Recipients Despite an Ineffectual T-Helper Response. PLoS ONE, 2008, 3, e3616.	1.1	4
158	Immune correlates of protection against HIV infection and how to elicit them. Mucosal Immunology, 2017, 10, 827-828.	2.7	4
159	Immunomodulation induced by tucaresol in HIV infection: results of a 16 week pilot Phase I/II trial. Antiviral Therapy, 2004, 9, 603-14.	0.6	3
160	Anti-Inflammatory Effects of Immunostimulation in Patients with COVID-19 Pneumonia. Journal of Clinical Medicine, 2021, 10, 5765.	1.0	3
161	Leishmania tarentolae as an Antigen Delivery Platform: Dendritic Cell Maturation after Infection with a Clone Engineered to Express the SARS-CoV-2 Spike Protein. Vaccines, 2022, 10, 803.	2.1	3
162	The breakdown of the cytokine network subsequent to human immunodeficiency virus infection. Mediators of Inflammation, 1995, 4, 315-321.	1.4	2

#	Article	IF	CITATIONS
163	Mucosal immunoglobulin A in HIV-exposed seronegative individuals. Aids, 2012, 26, 2247-2250.	1.0	2
164	Higher Levels of Peripheral Th17 T CD4+ Cells Are Associated With Immunological Non Response in HIV-Infected Patients Under Effective ART. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, e45-e47.	0.9	2
165	Granulocyte/monocyte apheresis induces sustained increases in CD4 T cells in HIV-1 infected patients with poor CD4 T cell restoration after suppression of viral replication by HAART. Journal of Biological Regulators and Homeostatic Agents, 2002, 16, 58-63.	0.7	2
166	PCP Occurring in HIV Patients Under HAART: Assessment of Specific Immunity Against P. carinii. Journal of Eukaryotic Microbiology, 2001, 48, 152s-152s.	0.8	1
167	Variants in the CYP7B1 gene region do not affect natural resistance to HIV-1 infection. Retrovirology, 2015, 12, 80.	0.9	1
168	Cell-Mediated Immunity in HIV-Infected Males With Human Papillomavirus–Related Anal Dysplastic Lesions. Clinical Infectious Diseases, 2016, 63, 1396-1398.	2.9	1
169	Early-Transmitted Variants and Their Evolution in a HIV-1 Positive Couple: NGS and Phylogenetic Analyses. Viruses, 2021, 13, 513.	1.5	1
170	The Modulation of Cholesterol Metabolism Is Involved in the Antiviral Effect of Nitazoxanide. Infectious Disease Reports, 2021, 13, 636-644.	1.5	1
171	Antiretroviral compounds affect the granule-dependent mechanisms of lysis in CD8 T cells. Retrovirology, 2006, 3, 1.	0.9	0
172	Plasma and PBMC miRNA Profile in Sexually HIV-1 Exposed Seronegative Individuals. AIDS Research and Human Retroviruses, 2014, 30, A83-A83.	0.5	0
173	Evolutionary Analysis Identifies an MX2 Haplotype Associated with Natural Resistance to HIV-1 Infection. AIDS Research and Human Retroviruses, 2014, 30, A24-A25.	0.5	O
174	Evaluation of Immune Activation in HIV-Infected and Uninfected African Individuals by Single-Cell Analysis of Cytokine Production. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 429-436.	0.9	0
175	Is there a risk of virus contamination through pneumoperitoneum during laparoscopic surgery in patients with COVID-19? A cadaveric study. Minerva Urology and Nephrology, 2022, 74, .	1.3	0
176	New Insights in the Fight against HIV. Cells, 2021, 10, 3549.	1.8	0